#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paraganglion neoplasm Glomerulonephritis rapidly progressive Mastocytosis Obliterative bronchiolitis Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Arterial tortuosity syndrome Bulbospinal muscular atrophy congenital Primary immunodeficiency syndrome Neutropenia Primitive neuroectodermal tumour Congenital disorder of glycosylation Thalassaemia Graft versus host disease Ichthyosis Chorioretinitis More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma Inclusion body myositis Glomerulonephritis membranoproliferative – Basic Information Chronic granulomatous disease – Diagnostics Cystic fibrosis lung Mantle cell lymphoma – Life with Disease Angiosarcoma recurrent Hairy cell leukaemia recurrent – Life with Disease Paraneoplastic neurological syndrome – Trials in Disease Mitochondrial myopathy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ipratropium Bromide Rilvegostomig Umeclidinium Folinic Acid Protease Imiquimod Niraparib Dabigatran Denosumab Sodium Hyaluronate For-6219 Rgx-202 Glucose Monohydrate Bepranemab Siremadlin Gtaexs617 Afm24 SODIUM FUSIDATE ATTR-01 LTX-002 SODIUM More therapies…

    Learn about Your Condition

    Vertigo Head and neck cancer stage III Post-acute COVID-19 syndrome Kidney transplant rejection Pancreatic carcinoma recurrent Amyotrophic lateral sclerosis Vulval cancer recurrent Aplasia pure red cell Bone sarcoma Rhabdomyosarcoma Pancreatitis chronic Cholangiosarcoma Notalgia paraesthetica Lung adenocarcinoma stage IV Ewing's sarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Ivosidenib
    Austria Belgium France Greece Hungary Ireland +5

  • Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Argipressin
    • Betamethasone Sodium Phosphate
    • Buclizine Hydrochloride
    Austria Belgium Bulgaria Czechia Denmark France +10

  • A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Belgium Bulgaria Czechia Finland France Germany +6

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Durvalumab
    Belgium Denmark France Germany Greece Italy +2

  • Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    Belgium Czechia France Germany Italy Lithuania +5

  • Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Trastuzumab
    • Trastuzumab Emtansine
    Belgium The Netherlands

  • Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Clear cell renal cell carcinoma
    • Endometrial cancer
    Investigated Drugs:
    • Raludotatug Deruxtecan
    Belgium Denmark France Italy Spain

  • Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Cytarabine
    • Daunorubicin Hydrochloride
    • Idarubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study of Livmoniplimab and Budigalimab Compared to Chemotherapy for Adults with Advanced Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Budigalimab
    • Docetaxel
    • Gemcitabine
    Belgium France Poland Spain
Previous Page
1 … 10 11 12 13 14 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!